Publication Topic

Wikoff D, Fitch S, Vincent M, Southall MD, Atillasoy E, Weinstein RD, Ejaz SD, Rhoden JD, Choksi N. Biological plausibility assessment of acetaminophen and occurrence of developmental neurological outcomes in humans. Abstract 4768, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025. (Honored as one of the Risk Assessment Specialty Section’s Top 10 Abstracts).

Mihalchik A. Strategies to evaluate over-the-counter drug degradants. Abstract 1252, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025.

Rogers JD, Patlewicz G, Baker E, Bettmann A, Clippinger A, Paul Friedman K. High-throughput safety pharmacology screening to better understand data-poor chemicals. Abstract 57, American Society for Cellular and Computation Toxicology 13^th Annual Meeting, Research Triangle Park, NC, October 2024.

Wharton GT, Becker C, Bennett D, Burcu M, Bushnell G, Ferrajolo C,… Movva N,…, Suh M, et al. 2024. Overview of global real-world data sources for pediatric pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 33(1):e5695; doi: 10.1002/pds.5695. PMID: 37690792.

Petrick J, Mihalchik A, Tiwary A, Kreidl L, Swartz C, Bhattarai N. Nonclinical safety evaluation of 1-monoacetin and 2-monoacetin as potential impurities in pharmaceutical excipients. Abstract 3107, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Robison TW, Heflich RH, Manjanatha MG, Elespuru R, Atrakchi A, Mei N, Ding W. 2021. Appropriate in vivo follow-up assays to an in vitro bacterial reverse mutation (Ames) test positive investigational drug candidate (active pharmaceutical ingredient), drug- related metabolite, or drug-related impurity. Mutat Res Gen Toxicol Environ Mutagen 868-869(Aug-Sept):503386; doi: 10.1016/j.mrgentox.2021.503386. PMID: 34454692.

Revollo JR, McKinzie PB, Robison TW, Dobrovolsky VN. 2021. Mutational signatures in T-lymphocytes of rats treated with N-propyl-N-nitrosourea and procarbazine. Environ Mol Mutagen 62(6):350-363; doi: 10.1002/em.22448. PMID: 34117657.

Ishida K, Werner J, Lafleur N, Wisler J, Wannberg S, Kalanzi J, Bussiere J, Monticello TM. 2021. Phosphatidylinositol 3-kinase δ-specific inhibitor-induced changes in the ovary and testis in the Sprague Dawley rat and cynomolgus monkey. Int J Toxicol 40(4):344-354; doi: 10.1177/109158211008175. PMID: 33866838.

Jaeschke H, Murray FJ, Monnot AD, Jacobson-Kram D, Cohen SM, Hardisty JF, Atillasoy E… Wikoff D, et al. 2021. Assessment of the biochemical pathways for acetaminophen toxicity: Implications for its carcinogenic hazard potential. Regul Toxicol Pharmacol 120(March):104859; doi: 10.1016/j.yrtph.2020.104859. PMID: 33388367.

Broome, C, Patel P, Jiang X, Iglesias-Rodriguez M, Fryzek J. Increased antidepressant use among newly diagnosed patients with cold agglutinin disease compared with other patients in a large US healthcare system. E-poster EP1180, presentation to European Hematology Association Virtual Congress, June 2021.

Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058. PMID: 32594093.

Bogdanfy MS, Lesnick J, Mangipudy R, Sistare FD, Colman K, Garcia-Tapla D, Monticello T, Blanset D. 2020. Tg.rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals: Industry survey of current practices. Int J Toxicol 39(3):198-206; doi: 10.1177/1091581820919896. PMID: 32372678.

Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. A budget impact model of Axicabtagene Ciloleucil in a US population of patients with relapsed/refractory large B-cell lymphoma (RR-LBCL). European Blood and Marrow Transplantation Meeting, Lisbon Portugal, 2018.

Hooda N, McFarlane T, Pasetka M, DeAngelis C. 2018. Investigating guideline-consistent anti-emetic prescribing practices at the Odette Cancer Centre (OCC). Poster for oral presentation seminar “Meet the Future Leaders in Research” at the Ontario Pharmacist Conference, Huntsville, ON, June 2018.

Winiwarter S, Ahlberg E, Watson E, Oprisiu I, Mogemark M, Noeske T, Greene N. 2018. In silico ADME in drug design–Enhancing the impact. ADMET DMPK 6(1):15-33; doi: 10.5599/admet.6.1.470.

Butler L, Guzzie-Peck P, Hartke J, Bogdanffy M, Will Y, Diaz D, Mortimer-Cassen E,.., Greene N, et al. Revised draft EMA guidance on early clinical trials: Potential impacts and industry response. Abstract P204, American College of Toxicology 2017 Annual Meeting, Palm Springs, CA, 2017. Int J Toxicol 37(1):75-76; doi: 10.1177/10915818177494, 2018.

Mihalchik AL, Rogers EN. 2018. Classes of compounds with GI tract toxicity. Chapter 13 in: Gad SC (ed), Toxicology of the Gastrointestinal Tract. CRC Press.

Prior H, Bottomley A, Champeroux P, Cordes J, Delphy E, Dybdal N, et al. 2016. Social housing of non-rodents during cardiovascular recording in safety pharmacology and toxicology studies. J Pharmacol Toxicol Methods 81(Sep-Oct):75–87; doi: 10.1016/j.vascn.2016.03.004. PMID: 27039257.

Doepker C, Lieberman HR, Smith AP, Peck JD, El-Sohemy A, Welsh BT. 2016. Caffeine: Friend or foe? Annu Rev Food Sci Technol 7(Feb):117-137; doi: 10.1146/annurev-food-041715-033243.

Ulrich K. Inhalation toxicology – Regulatory aspects for pharmaceuticals. Presentation to In Vitro Toxicology Society Annual Meeting, Birmingham, UK, 2015.